JAZZ PATAGONIA (Parkinson's Disease)
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson’s disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.
Inclusion Criteria:
- 40 years to 80 years
- Parkinson’s Disease (full criteria in link below)
What to Expect
Participants will be randomized 1:1 to receive suvecaltamide or placebo and stratified by the Essential Tremor Rating Scale (TETRAS) composite outcome score (≤ 17 or > 17) as assessed at baseline
For more information click the link below or contact Heather MacNamara at hmacnamara@dentinstitute.com or 716-819-4117